Drug · DIN 02473100
HADLIMA PUSHTOUCH
SINGLE-DOSE AUTO-INJECTOR
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since February 19, 2021; first marketed February 19, 2021.
- Drug Identification Number (DIN)
- 02473100
- Company (DIN owner)
- Samsung Bioepis Co., LtdIncheon, Incheon, Korea, Republic Of
- Schedule
- Prescription; Schedule d
- Dosage form
- Solution
- Route
- Subcutaneous
- Therapeutic class (ATC)
- Adalimumab L04AB04
- Class
- Human
- Record last updated
- August 17, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| ADALIMUMAB | 40 MG | 0.8 ML |
Notices of Compliance
Health Canada approvals that name this DIN.
- May 8, 2018: NOC 20840New Drug Submission (NDS)
- May 8, 2018: NOC 20841New Drug Submission (NDS)
Other DINs named HADLIMA PUSHTOUCH
- DIN 02533480 · Marketed